Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors

Publisher： John Wiley & Sons Inc

E-ISSN： 1445-5994|48|S2|5-13

ISSN： 1444-0903

Source： INTERNAL MEDICINE JOURNAL, Vol.48, Iss.S2, 2018-02, pp. : 5-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 24-32

John Wiley & Sons Inc

Access to resources Recommend Favorite

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 683-688

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort

By  

Acta Haematologica, Vol. 130, Iss. 1, 2013-01 ,pp. : 16-22

Karger

Access to resources Recommend Favorite

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia

By  

THE JOURNAL OF PATHOLOGY, Vol. 237, Iss. 1, 2015-09 ,pp. : 14-24

John Wiley & Sons Inc

Access to resources Recommend Favorite

A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 4, 2015-08 ,pp. : 391-397

John Wiley & Sons Inc

Access to resources Recommend Favorite